The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.

Renowned molecular diagnostics provider Cepheid CPHD recently entered into a non-exclusive distribution agreement with Henry Schein Medical, the Medical business of one of the leading healthcare ...

Add Yahoo as a preferred source to see more of our stories on Google. By Natalie Grover (Reuters) - Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 ...

Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...

SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

Cepheid's performance in the first quarter was driven by robust growth in clinical product sales resulting from test utilization in the emerging HAI test market for Xpert MRSA, continued adoption of ...

Cepheid (NAS: CPHD) carries $32.2 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could this ...

A new diagnostic test for the novel coronavirus will return results in just 45 minutes, four times faster than existing machines. But the test, emergency use of which was cleared by the Food and Drug ...

Cepheid 's ( CPHD) sales under the HBDC (high burden developing countries) program are likely to get a boost from a $30 million funding approval from UNITAID. The approved fund would go a long way to ...

Shares jump on the news that the company is being bought out by Danaher. Danaher has offered to by Cepheid for $4 billion in cash, valuing shares at $53 each. That represents a premium of 54% based on ...

Shares of molecular diagnostics provider CepheidCPHD slumped 14.2% in after-hours trading yesterday, following the release of bleak preliminary results for its upcoming third quarter and revised full ...